Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
Sell
-20,300
Closed -$2.01M 766
2025
Q4
$2.01M Buy
+20,300
New +$1.96M 0.05% 314
2024
Q2
Sell
-20,300
Closed -$1.16M 518
2024
Q1
$1.16M Buy
+20,300
New +$1.22M 0.04% 258
2023
Q3
Sell
-13,500
Closed -$840K 415
2023
Q2
$840K Buy
+13,500
New +$902K 0.03% 262
2022
Q3
Sell
-20,300
Closed -$1.54M 430
2022
Q2
$1.54M Buy
+20,300
New +$1.54M 0.08% 223
2017
Q2
Sell
-6,500
Closed -$869K 360
2017
Q1
$869K Buy
+6,500
New +$828K 0.04% 258

Other funds holding INCY

J. Goldman & Co's INCY Position: Q2 2017 in Review

J. Goldman & Co sold out of Incyte (INCY) in Q2 2017, closing a stake of 30,000 shares — an estimated $4.01M sold.

J. Goldman & Co first reported a position in INCY in Q4 2016 and held it in 2 quarters. The position peaked at $7.82M in Q4 2016. 493 funds tracked by Wall St. Rank hold INCY as of Q2 2017.

  • J. Goldman & Co reported no remaining Incyte position as of Q2 2017 after selling out during the quarter.
  • J. Goldman & Co sold 30,000 Incyte shares in Q2 2017, an estimated $4.01M.
  • J. Goldman & Co first reported a position in Incyte in Q4 2016 and held it in 2 quarters.
  • J. Goldman & Co's Incyte position peaked at $7.82M in Q4 2016.
  • 493 funds tracked by Wall St. Rank held Incyte as of Q2 2017.

Based on J. Goldman & Co's 13F filing for Q2 2017, filed 14 Aug 2017.